Paclitaxel/Taxol / GastroP Cancer Research Results

PacT, Paclitaxel/Taxol: Click to Expand ⟱
Features:
Paclitaxel (brand name Taxol) is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. Administered by intravenous injection.
Derived from a natural product, Taxol (from Pacific Yew Tree).
Paclitaxel is a drug (chemotherapy; a taxane). Its dominant anticancer mechanism is microtubule stabilization, which disrupts normal mitosis and drives mitotic arrest/stress signaling that can culminate in apoptosis.


Paclitaxel – Cancer Pathway Matrix

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Microtubule stabilization → Mitotic arrest Mitotic progression ↓; spindle dynamics impaired; cell division blocked Proliferating normal cells affected R, G Core cytotoxic mechanism Binds β-tubulin and stabilizes microtubules, preventing normal depolymerization required for mitosis.
2 Spindle assembly checkpoint activation Prolonged mitotic arrest → mitotic catastrophe or apoptosis Checkpoint stress in dividing tissues R, G Mitotic stress execution Cell fate depends on whether arrest resolves via apoptosis or mitotic slippage.
3 Intrinsic apoptosis (mitochondrial pathway) Caspase activation ↑; BAX/mitochondrial signaling engaged (context) Limited unless stressed G Cell death execution Often downstream of prolonged mitotic stress and mitochondrial perturbation.
4 ROS generation (secondary) ROS ↑ (context-dependent); oxidative stress amplification Oxidative stress possible in sensitive tissues R, G Stress amplifier ROS rise appears secondary to mitotic and mitochondrial dysfunction; may enhance apoptosis.
5 Nrf2 antioxidant response (adaptive) Nrf2 ↑ in some tumors; antioxidant buffering ↑; resistance potential Protective antioxidant signaling G Adaptive resistance axis Not a direct paclitaxel target; elevated Nrf2 may reduce drug sensitivity.
6 Drug resistance mechanisms P-glycoprotein (MDR1) ↑; β-tubulin alterations; survival rewiring — G Treatment failure driver Efflux pumps and tubulin adaptations are major clinical resistance mechanisms.
7 Myelosuppression — Neutropenia risk ↑ G Dose-limiting toxicity Bone marrow suppression is a primary clinical constraint.
8 Peripheral neuropathy — Sensory neuropathy risk ↑ G Dose-limiting toxicity Likely related to microtubule disruption in axonal transport.

Time-Scale Flag (TSF):
P = 0–30 min (drug binding begins)
R = 30 min–3 hr (mitotic stress signaling, ROS changes)
G = >3 hr (apoptosis, resistance adaptation, tissue toxicities)



GastroP, GastroProtective: Click to Expand ⟱
Source:
Type:

GastroProtective refers to an effect that helps protect the gastrointestinal mucosa, especially the stomach, from injury caused by acid, NSAIDs, alcohol, infection, oxidative stress, or inflammation. Gastroprotective actions may involve enhancement of mucus and bicarbonate defenses, preservation of mucosal blood flow, reduction of oxidative damage, suppression of inflammatory signaling, and support of epithelial repair. In cancer and IBD-related contexts, gastroprotective or broader mucosal-protective effects may be relevant when a compound reduces treatment-related GI injury, limits inflammatory mucosal damage, or helps preserve barrier integrity, although this term is supportive and protective rather than a direct anticancer mechanism.
Scientific Papers found: Click to Expand⟱
7290- PacT,  Aidi,    Clinical efficacy and safety of Aidi injection plus paclitaxel-based chemotherapy for advanced non-small cell lung cancer: A meta-analysis of 31 randomized controlled trials following the PRISMA guidelines
Dose↝, QoL↑, hepatoP↑, GastroP↑, chemoP↑, Dose↝,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Barriers & Transport(tgid=15) ⓘ

GastroP↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 2,  

Functional Outcomes(tgid=23) ⓘ

chemoP↑, 1,   hepatoP↑, 1,   QoL↑, 1,  
Total Targets: 5

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: GastroP, GastroProtective
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:182  Target#:1459  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page